Irinotecan
SHARE
Molecule Summary
| Uses | Metastatic Colorectal Cancer |
| Therapy | Anti-Neoplastic |
| Side Effects | Diarrhoea, Low Blood Counts, Nausea, Hair Loss |
Assurance
available
Regulated
Molecule Description
Irinotecan is a prescription anticancer medication belonging to the class of drugs known as topoisomerase I inhibitors ( camptothecin derivatives). It is primarily used for the treatment of advanced or metastatic colorectal cancer. In the body, irinotecan is converted to an active substance called SN-38. It blocks an enzyme called topoisomerase I, which cancer cells need to copy and repair their DNA. This causes DNA damage and prevents cancer cells from growing and multiplying, eventually leading to cancer-cell death.
Irinotecan is given as an intravenous (IV) infusion by a healthcare professional. Because irinotecan can cause significant side effects, your doctor will monitor your blood counts, liver function, and symptoms such as diarrhoea and signs of infection during treatment.
Irinotecan is a prescription-only medicine and should be used strictly under medical supervision. The treatment plan is decided by the treating doctor based on the condition being treated, your body response and the other medicines you are receiving. Do not change, stop or repeat a dose on your own.
Before starting Irinotecan, tell your doctor about all your existing medical conditions, especially heart, liver or kidney problems, and about every medicine, vitamin, supplement and herbal product you take. Tell your doctor if you are pregnant, planning a pregnancy or breastfeeding. Regular blood tests and clinical check-ups are usually needed during treatment so that side effects are picked up early.
Uses
- Treatment of metastatic colorectal cancer.
Contraindications
When should one not use Irinotecan
- If you have a known hypersensitivity or severe allergic reaction to irinotecan hydrochloride trihydrate or any of the other ingredients of the medicine.
Side effects
Common side effects of this drug are:
- Delayed onset of diarrhea (occurring more than 24 hours after infusion, which can be severe and dehydrating)
- Bone marrow suppression leading to neutropenia (low white blood cell count increasing infection risk), anemia, and thrombocytopenia (low paltelet count)
- Nausea, vomiting, and loss of appetite
- Temporary hair loss (alopecia)
- Asthenia (weakness) and fatigue
- Early diarrhea and acute cholinergic syndrome (occurring during or shortly after infusion, characterized by sweating, fall in heart rate, abdominal cramping, lacrimation, and salivation)
- Abdominal pain and mild constipation
- Mild transient liver enzyme and bilirubin elevations
- Fever and transient speech disorders during infusion
- Severe, life-threatening neutropenia and bone marrow failure
- Interstitial pulmonary disease or severe shortness of breath
- Severe allergic or anaphylactoid reactions
Precautions and Warnings
Pregnancy
Breast Feeding
Driving
Alcohol
Other General Warnings
Talk to your doctor if
- You experience severe, prolonged diarrhea (especially if it begins more than 24 hours after your infusion), as this requires immediate medical attention and aggressive hydration.
- You develop a fever, chills, or signs of infection while your blood counts are low.
- You experience sudden shortness of breath, cough, or breathing difficulties.
- You have a history of Gilbert's syndrome, as specialized monitoring is required.
- Keep all scheduled blood test appointments so your doctor can check your white blood cell counts and liver function before every cycle.
- Ensure you have your prescribed anti-diarrheal medication at home before your infusion begins, and know exactly how to use it at the very first sign of late diarrhea.
- Report any fever, chills, dizziness, or persistent diarrhea to your medical team immediately.
- Watch for early cholinergic symptoms during your infusion (like excessive sweating or abdominal cramps) and notify your nurse right away so they can treat it.
- Inform all your healthcare providers that you are taking this medication before undergoing any other medical procedures or dental work.
Mode of Action
How Does It Work?
Irinotecan is a topoisomerase I inhibitor. After entering the body, it is converted into an active substance called SN-38. SN-38 blocks an enzyme called topoisomerase I, which cancer cells need to copy and repair their DNA. This causes DNA damage and stops cancer cells from growing and multiplying, eventually leading to their death
Interactions
Interactions with other medicines
- Avoid St. John's wort (a herbal supplement), as it can significantly decrease irinotecan blood levels and effectiveness.
- Avoid live or attenuated vaccines during treatment and for several months afterward due to immunosuppression.
- Inform your doctor about all prescription drugs, over-the-counter medicines, and herbal supplements you are taking, especially strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin, anticonvulsants) which alter drug clearance.
- Use caution with neuromuscular blocking agents, as irinotecan can prolong their activity.
Interactions with food items
Maintain a well-balanced diet and consume abundant fluids (drinking plenty of water daily) to stay hydrated, especially if experiencing gastrointestinal side effects.
Dosage
Overdose
If an overdose is suspected, emergency medical intervention must be initiated immediately in a hospital setting. Symptoms of an overdose can include severe myelosuppression, profound neutropenia, and severe gastrointestinal complications. Management involves supportive hospital care, growth factor administration, aggressive anti-diarrheal protocols, and close clinical monitoring.
Missed a Dose
If you miss a scheduled infusion appointment, contact your hospital or oncology clinic immediately to reschedule. Do not try to make up a missed session on your own, as your doctor will safely adjust your treatment schedule based on your blood counts and recovery status.
Frequently Asked Questions (FAQs)
Articles
View AllDid you find this helpful?
References:
- DailyMed. Irinotecan prescribing information. 2026 [Cited 17th Sep 2026]
- electronic medicines compendium (emc). Irinotecan Summary of Product Characteristics. 2026 [Cited 17th Sep 2026]
- Central Drugs Standard Control Organisation (CDSCO). Drugs@CDSCO [Internet]. New Delhi: Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. 2026 [Cited 17th Sep 2026]
Explore More at Pharmeasy
Why trust PharmEasy?
# ONE OF INDIA'S MOST TRUSTED HEALTHCARE PLATFORM
CODAvailable
100%Genuine Medicine
30 DAYReturn Policy









